SCHEMBL5335503

SCHEMBL5335503

NCCCN1CC(Oc2ccc(F)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.43
CCR1 P32246 1/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
GRIN1 Q05586 4/20 0.40
GRIN2B Q13224 4/20 0.40
HSD17B10 Q99714 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39
HTR2A P28223 1/20 0.39
DRD3 P35462 1/20 0.39
ESR1 P03372 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL7255793 0.98 CCR3 (0.43) CCR3CCR1HTTMEN1LMNA
SCHEMBL9556062 0.85 HTR2A (0.49) CCR3CCR1HTTMEN1LMNA
SCHEMBL5334415 0.78 SLC6A4 (0.49) CCR3MEN1KMT2AKDM4EALDH1A1
SCHEMBL5335497 0.78 GRIN1 (0.45) CCR3CCR1HTTKDM4EGRIN1
SCHEMBL14612865 0.77 HRH3 (0.46) HRH3GRIN1GRIN2B
SCHEMBL5331901 0.77 GRIN1 (0.42) CCR3CCR1HTTKDM4EGRIN1
SCHEMBL5331909 0.77 GRIN1 (0.42) CCR3CCR1HTTKDM4EGRIN1
Hydrochloric Acid SCHEMBL5338438 0.76 GRIN1 (0.41) CCR3CCR1HTTKDM4EGRIN1
Hydrochloric Acid SCHEMBL5338443 0.76 GRIN1 (0.41) CCR3CCR1HTTKDM4EGRIN1
SCHEMBL21266009 0.75 ESR1 (0.55) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288537-B2 Azetidine derivatives as CCR-3 receptor antagonists NOVARTIS AG (CH) 2007-10-30 US disclosed
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists NOVARTIS AG (CH) 2005-10-06 US disclosed
EP-1487435-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2004-12-22 EP disclosed
WO-2003077907-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2003-09-25 WO disclosed
WO-2003007939-A1 AZETIDINE DERIVATIVES AND THEIR USE AS CCR3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists CCR3, CCR1, CCR9 CCR3 1/4885CCR1 2/4885HTT 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.